IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility
08 août 2023 08h00 HE
|
IN8bio, Inc
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline of innovative gamma-delta T cell therapiesThe new site supports...
IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting
05 juin 2023 08h00 HE
|
IN8bio, Inc
100% of treated patients (n=8) to date have exceeded historical median progression-free survival, with two patients that received three doses remaining progression-free at 23.5 and 19.4 months,...
IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
17 mai 2023 08h00 HE
|
IN8bio, Inc
Preclinical results showcase the potential for the strong synergistic combination of chemotherapy and gamma-delta T cell therapy to target solid tumors beyond the brain The DeltEx platform is the...
IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
12 mai 2023 08h00 HE
|
IN8bio, Inc
Presented positive INB-100 data showing long-term complete remissions (CR) and elevated gamma-delta T cell levels in 100% of evaluable treated leukemia patients; Dose Level 2 selected as the...
IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting
02 mai 2023 17h08 HE
|
IN8bio, Inc
Preclinical data demonstrates that gamma-delta T cells have the ability to target other solid tumors such as ovarian cancer, supporting the development of these technologies outside of brain tumorsThe...
IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors
01 mai 2023 08h00 HE
|
IN8bio, Inc
Dr. Jeremy Graff spent 17 years at Eli Lilly and Company, where he built and led the translational oncology group, supporting and advancing 31 clinical assets in Eli Lilly’s oncology portfolioHe is a...
IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting
26 avr. 2023 10h00 HE
|
IN8bio, Inc
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced an...
IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma
25 avr. 2023 08h00 HE
|
IN8bio, Inc
First-ever orphan drug designation for genetically modified gamma-delta T cell therapies This orphan drug designation offers potential 7-year market exclusivity for both autologous (INB-400) and...
IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023
24 avr. 2023 08h00 HE
|
IN8bio, Inc
INB-100 treatment has achieved durable 100% complete remission (CR) in treated patients, including high-risk acute myeloid leukemia (AML) patients and a patient with acute lymphoblastic leukemia (ALL)...
IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023
17 avr. 2023 09h00 HE
|
IN8bio, Inc
INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the ability to target cancer cells while sparing healthy tissue when both express the CAR-targeted antigen.CAR...